Compare GDRX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | PSNL |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.9M | 729.1M |
| IPO Year | 2020 | 2019 |
| Metric | GDRX | PSNL |
|---|---|---|
| Price | $2.24 | $6.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $3.86 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 3.4M | 1.3M |
| Earning Date | 05-26-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 33.58 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $796,853,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $16.94 |
| Revenue Next Year | $5.75 | $36.58 |
| P/E Ratio | $24.56 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.77 | $2.83 |
| 52 Week High | $5.61 | $11.50 |
| Indicator | GDRX | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 34.61 |
| Support Level | $2.11 | $4.31 |
| Resistance Level | $2.59 | $6.94 |
| Average True Range (ATR) | 0.15 | 0.71 |
| MACD | 0.02 | -0.19 |
| Stochastic Oscillator | 62.55 | 5.95 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.